妊娠对烟酰胺药代动力学及代谢的影响
在健康妊娠24-33周女性与未妊娠女性中各6例中,单次口服烟酰胺1g后,烟酰胺及其中间代谢物MNA的血浆AUC0→24无显著差异,但终末代谢物M2PY的AUC0→24在妊娠组显著降低,且M2PY肾清除率显著升高。
要点
- 妊娠不显著改变烟酰胺及其中间代谢物MNA的系统暴露。
- 妊娠期M2PY系统暴露降低,与M2PY肾清除率升高相关。
- 烟酰胺及其代谢物总生成清除率在妊娠与非妊娠间无差异。
核心结论
- 妊娠不显著改变烟酰胺及MNA的药代动力学,但M2PY系统暴露因肾清除增加而降低。
研究设计与样本
- 健康妊娠24-33周女性与未妊娠女性各6例,单次口服烟酰胺1g后采集血样和尿样,采用非房室分析比较药代动力学参数。
主要发现
- 烟酰胺血浆AUC0→24中位数在妊娠组为463 μM*hour,非妊娠组为510 μM*hour,P=0.430。
- MNA血浆AUC0→24中位数在妊娠组为89.1 μM*hour,非妊娠组为83.8 μM*hour,P=0.515。
- M2PY血浆AUC0→24中位数在妊娠组为218 μM*hour,显著低于非妊娠组的597 μM*hour,P<0.001。
- M2PY肾清除率在妊娠组为10.5 L/h,显著高于非妊娠组的7.5 L/h,P=0.002。
- 烟酰胺肾清除率、MNA肾清除率及总代谢物生成清除率组间无显著差异(P分别为0.184、0.180、0.405)。
临床怎么用
- 妊娠期使用烟酰胺时,其母体暴露及MNA暴露预期不因妊娠而显著改变。
- 需关注妊娠期M2PY暴露降低可能带来的代谢产物相关效应变化。
局限性
- 样本量较小(每组6例),研究人群为妊娠24-33周健康女性。
- 仅评估单次口服1g烟酰胺后的短期药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In pre-eclampsia models, nicotinamide (NAM) has protective effects in pre-eclampsia and is being evaluated as a therapeutic nutraceutical in clinical studies. NAM undergoes extensive hepatic metabolism by NAM N-methyltransferase to methylnicotinamide (MNA), which is subsequently metabolized to methyl-2-pyridone-5-carboxamide (M2PY) by aldehyde oxidase. However, the pharmacokinetics of NAM and its major metabolites has never been studied in pregnant individuals. Blood samples were collected before and 1, 2, 4, 8, and 24 hours after single 1 g oral NAM dose in healthy pregnant (gestational age 24-33 weeks) and nonpregnant female volunteers (n = 6/group). Pooled urine was collected from 0 to 8 hours. NAM, MNA, and M2PY area under the concentration-time curve (AUC) data were analyzed by noncompartmental analysis. No difference in the plasma AUC0→24 of NAM (median (25%-75%): 463 (436-576) vs. 510 (423, 725) μM*hour, P = 0.430) and its intermediate metabolite MNA (89.1 (60.4, 124.4) vs. 83.8 (62.7, 93.7) μM*hour, P = 0.515) was observed in pregnant and nonpregnant volunteers, respectively; however, the terminal metabolite M2PY AUC0 → 24 was significantly lower in pregnant individuals (218 (188, 254) vs. 597 (460, 653) μM*hour, P < 0.001). NAM renal clearance (CLR ; P = 0.184), MNA CLR (P = 0.180), and total metabolite formation clearance (P = 0.405) did not differ across groups; however, M2PY CLR was significantly higher in pregnant individuals (10.5 (9.3-11.3) vs. 7.5 (6.4-8.5) L/h, P = 0.002). These findings demonstrate that the PK of NAM and systemic exposure to its intermediate metabolite MNA are not significantly altered during pregnancy, and systemic exposure to NAM's major metabolite M2PY was reduced during pregnancy due to increased renal elimination.
引用
- Fashe MM, Le TV, Gower MN, et al. Impact of Pregnancy on the Pharmacokinetics and Metabolism of Nicotinamide in Humans. Clin Pharmacol Ther. 2024. PMID: 38093631. doi:10.1002/cpt.3146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。